Bitte wählen Sie:

Universitätsklinikum Essen

Kostenlose Hotline

+49 (0) 201 - 723 - 2000 Zum Kontaktformular

Schnelleinstieg über:



Molecular Tumorpathology - Grüner lab

Dr. rer. nat. Barbara M. Grüner

Emmy Noether Group Leader


+49 201 723 8142




Madeleine Dorsch, M.Sc., Postdoctoral Scientist





Philip Dujardin, M.Sc., PhD student






Eva Hahn, Technician





Marc Biller, cand. med.





Sebastian Urban, M.Sc., PhD student









Anna Baginska, M.Sc., PhD student












Several factors contribute to the poor outcome of cancer patients, but the ability of cancer cells to leave the primary tumor and establish inoperable metastases is a major impediment to successful therapy. Although most cancer patients die of complications resulting from the effects of metastases, the basic molecular and cellular mechanisms that endow a tumor cell with the ability to leave the primary tumor, survive during transit through the blood, and establish and maintain a new tumor in a secondary organ remain incompletely understood.

Using advanced in vivo models of metastatic cancer and combining those with powerful quantitative DNA-barcoding technology we are scrutinizing the molecular mechanisms that allow cancer cells to metastasize and how this process can be inhibited. Given most cancers’ high intrinsic resistance to established and newly developed targeted therapies we furthermore use these models to study the underlying mechanisms of resistance and how they can be overcome, getting one step closer to efficient cancer therapy.





A full list of publications can be found here


Selected publications

[1] Chiou SH, Dorsch M, Kusch E, Naranjo S, Kozak MM, Koong AC, Winslow MM, Grüner BM. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance, Scientific Reports 2018 Sep 18;8(1):14008.

[2] Chuang CH, Greenside PG, Rogers ZN, Brady JJ, Yang D, Ma RK, Caswell DR, Chiou SH, Winters AF, Grüner BM, Ramaswami G, Spencley AL, Kopecky KE, Sayles LC, Sweet-Cordero EA, Li JB, Kundaje A, Winslow MM. Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis, Nat Medicine 2017 Mar;23(3):291-300

[3] Grüner BM*, Schulze CJ*, Yang D, Ogasawara D, Dix MM, McFarland CD, Chuang CH, Rogers ZN, Brown JM, Cravatt BF, Bogyo M, Winslow MM. An in vivo multiplexed small molecule screening platform to identify inhibitors of metastatic seeding, Nature Methods 2016 Oct 13(10):883-9  *both authors contributed equally to this work

[4] Denny SJ, Yang D, Chuang CH, Brady JJ, Lim JS, Grüner BM, Chiou SH, Schep A, Baral J, Hamard C, Antoine M, Wislez M, Kong C, Connolly AJ, Park KS, Sage J, Greenleaf WJ, Winslow MM. Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility Cell 2016 July 14;166, 1–15

[5] Ardito CM*, Grüner BM*, Lubeseder-Martellato C, Takeuchi KK, DelGiorno KE, Carpenter ES, Halbrook CJ, Pal D, Hall JC, Mazur PK, Briel T, Herner A, Threadgill DG, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, and Siveke JT. EGF Receptor is Required for Kras-induced Pancreatic Tumorigenesis. Cancer Cell. 2012 Sep 11;22(3):304-17  *both authors contributed equally to this work





Emmy Noether Group Molecular Tumorpathology     

West German Cancer Center                                          
Department of Medical Oncology                                             
University Hospital Essen 

WTZ-F R1.001                                                        
Hufelandstr. 55                                                                          
45147 Essen, Germany

For inquiries regarding open Masterstudent, PhD or Postdoc positions please send your CV and a short cover letter to Barbara Grüner - barbara.gruener[at]

+49 201 723 8142 +49 201 723 6825